Reliance on Foreign Drug Regulator Decisions

Summary#

• The federal government published a proposed order called the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs.
• If adopted, Health Canada would be able to treat parts of a drug application as already examined when a trusted foreign regulator has reviewed the same information — a change designed to speed some drugs to market. Public comments are open for 70 days and some parts would take effect on April 1, 2027 if the order is finalized.

What it does#

• Allows certain parts of a Canadian drug review to be “deemed” complete based on a decision or documents from selected foreign regulatory authorities (FRAs).
• Sets out three ways deeming could be used:
  • General Deeming — rely on an FRA decision already made for a foreign drug.
  • 120-day Filing — let a manufacturer file in Canada within 120 days of filing with an FRA so Health Canada can start work early.
  • Joint Reviews — use documents created during a joint review with one or more FRAs.
• Only applies to specific classes of new human and veterinary drugs listed in a separate document called the List of Classes of Drugs and Foreign Regulatory Authorities for the Purposes of Reliance on Decisions or Documents (IbR List). That list will be updated over time.
• Requires the manufacturer to show:
  • the Canadian product has the same active ingredient, strength, form and route as the foreign product;
  • any differences would not affect safety or effectiveness; and
  • any post-market conditions set by the FRA can be met or matched in Canada.
• Health Canada would still review Canadian-specific parts of an application, such as labelling and brand name, the withdrawal period for food-producing animals, and later the risk management plans that become mandatory on April 1, 2027.
• Intellectual property protections (data protection, patent-related rules, supplementary protection) would remain unchanged.

Who's affected#

• Drug manufacturers, especially multinational companies that already have authorizations from the listed FRAs.
• Generic and biosimilar makers could be affected, though use of the order for comparative submissions is being considered separately.
• Patients and clinicians who may get some drugs on the Canadian market earlier — examples mentioned include pediatric formulations and some veterinary products not currently available in Canada.
• Health Canada, which would change how it allocates review resources.
• Health technology assessment bodies (HTAs), provinces and territories, and the pan-Canadian Pharmaceutical Alliance (pCPA), because earlier authorizations can shift downstream review, pricing and reimbursement work.
• Small Canadian drug companies are unlikely to benefit much at first, since they typically do not have foreign authorizations to rely on.
• It is not yet clear which specific drug classes or foreign regulators will be listed on the IbR List; that detail will determine who can actually use the approach.

Why it matters#

• The government’s goal is to get some new drugs to Canadians faster by avoiding duplicate review work when trusted foreign regulators have already examined the same science.
• Health Canada expects fewer information requests and some resource savings, which could let the department focus on the most complex reviews. The regulatory cost–benefit estimate shows minimum costs of $1.33 million PV (about $190,104 per year) and minimum benefits of $3.69 million PV (about $525,825 per year), for a projected net benefit of $2.36 million PV (about $335,721 per year) over 10 years.
• Real-world trade-offs: faster access and lower review burden versus concerns about uneven effects on domestic manufacturers and the need for HTAs and payers to adapt.
• Safety checks remain: manufacturers must disclose differences from the foreign product and cannot use deeming if differences could hurt safety or effectiveness; Health Canada retains final authority and will require post-market reporting.